Time to treatment failure (any reason related to treatment) All participants Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to treatment failure (any reason related to treatment) All… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: focal onset seizures Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: generalised onset seizures (tonic‐clonic only) Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin monotherapy (low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) All participants Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to first seizure (post‐randomisation) All participants Range of compared with phenytoin monotherapy (low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) Subgroup: focal onset seizures Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to first seizure (post‐randomisation) Subgroup: focal onset… compared with phenytoin monotherapy (low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) ‐ stratified by epilepsy type: generalised onset seizures (tonic‐clonic only) Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to first seizure (post‐randomisation) Subgroup: generalised… compared with phenytoin monotherapy (low certainty).
1 finding from 1 review
Remission · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) All… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to achieve 12‐month remission (seizure‐free period) Subgroup: focal onset seizures Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to 12‐month remission ‐ stratified by epilepsy type ‐ Generalized onset seizures (tonic‐clonic only) Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Seizure freedom · participants with generalised epilepsy
Summary of findings: needle acupuncture plus valproate showed no clear difference in seizure freedom ( compared with valproate alone (moderate certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · participants with generalised epilepsy
Summary of findings: needle acupuncture plus valproate showed no clear difference in 50% or greater reduction in seizure frequency ( compared with valproate alone (low certainty).
1 finding from 1 review
Post‐treatment quality of life (QOLIE‐31 score, which has a range of 0‐200, with higher score indicates better quality of life) ( · participants with generalised epilepsy
1 finding from 1 review
Frequency of adverse effects ‐ dizziness ( · participants with generalised epilepsy
Summary of findings: needle acupuncture plus valproate showed no clear difference in frequency of adverse effects ‐ dizziness ( compared with valproate alone (low certainty).
1 finding from 1 review
Frequency of adverse effects ‐ malaise ( · participants with generalised epilepsy
Summary of findings: needle acupuncture plus valproate showed no clear difference in frequency of adverse effects ‐ malaise ( compared with valproate alone (low certainty).
1 finding from 1 review
Nausea · participants with generalised epilepsy
Summary of findings: needle acupuncture plus valproate showed no clear difference in frequency of adverse effects ‐ nausea ( compared with valproate alone (low certainty).
1 finding from 1 review
Frequency of adverse effects ‐ sleepiness ( · participants with generalised epilepsy
Summary of findings: needle acupuncture plus valproate showed no clear difference in frequency of adverse effects ‐ sleepiness ( compared with valproate alone (low certainty).
1 finding from 1 review
Recurrent seizure at 6 months · children with febrile seizures
Continuous oral valproate showed no clear difference in recurrent seizure at 6 months compared with placebo or no treatment (low certainty).
1 finding from 1 review
Recurrent seizure at 12 months · children with febrile seizures
Continuous oral valproate showed no clear difference in recurrent seizure at 12 months compared with placebo or no treatment (low certainty).
1 finding from 1 review
Recurrent seizure at 18 months · children with febrile seizures
It is very uncertain whether continuous oral valproate changes recurrent seizure at 18 months compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Recurrent seizure at 24 months · children with febrile seizures
Continuous oral valproate showed no clear difference in recurrent seizure at 24 months compared with placebo or no treatment (low certainty).
1 finding from 1 review